

Cevostamab

Cat. No.:	HY-P99601
CAS No.:	2249888-53-5
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells ^{[1][2]} .
IC₅₀ & Target	FcRH5; CD3 ^{[1][2]}
In Vitro	Cevostamab shows a dose-dependent and robust killing of B cells and bone marrow plasma cells from peripheral blood mononuclear cell (PBMC)/BMPC samples from cynomolgus monkey ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cevostamab (0.5 mg/kg; i.v.; once weekly for) suppresses the growth of established MOLP-2 tumors in mice reconstituted with human immune cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Li J, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. *Cancer Cell*. 2017 Mar 13;31(3):383-395.

[2]. Hosny M, et al. Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. *J Clin Med*. 2021 Oct 6;10(19):4593.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA